Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jong-Mu Sun

Showing results (161-170 of 303) with videos related to

Pageof 31
Sort By:
The Korean Journal of Internal Medicine|April 4, 2020
Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancerSung Hee Lim, Jong-Mu Sun, Joohyun Hong, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2021
Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experienceYong-Pyo Lee, Byeong-Ho Jeong, Yeonghee Eun, et al.
The Annals of Thoracic Surgery|February 21, 2026
Prognosis of Isolated Cervical Node Recurrence Following Esophagectomy With Two-Field Lymphadenectomy for Esophageal Squamous Cell CarcinomaYeong Jeong Jeon, Jeong A Son, Junghee Lee, et al.
Urologic Oncology|December 24, 2013
FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapyJi-Youn Sung, Jong-Mu Sun, Byong Chang Jeong, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 15, 2022
Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 TrialJiyun Lee, Jiae Koh, Hee Kyung Kim, et al.
Esophagus : Official Journal of the Japan Esophageal Society|December 11, 2023
Prognostic role of pathologic status other than complete response after neoadjuvant therapy followed by surgery in esophageal squamous cell carcinomaSeong Yong Park, Junghee Lee, Dongryul Oh, et al.
Cancer Research and Treatment|October 17, 2023
Neoadjuvant Nivolumab Therapy for Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II StudySehhoon Park, Yurimi Lee, Jiyun Lee, et al.
The Lancet. Oncology|December 25, 2025
Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trialChih-Hung Hsu, Zhihao Lu, Shegan Gao, et al.
Lung Cancer (Amsterdam, Netherlands)|August 14, 2009
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancerJong-Mu Sun, Do-Youn Oh, Se-Hoon Lee, et al.
Journal of Cancer Research and Clinical Oncology|June 1, 2011
Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancySoohyeon Lee, Youngwook Kim, Jong-Mu Sun, et al.
Pageof 31

Showing results (161-170 of 303) with videos related to

Sort By:
Pageof 31
The Korean Journal of Internal Medicine|April 4, 2020
Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancerSung Hee Lim, Jong-Mu Sun, Joohyun Hong, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2021
Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experienceYong-Pyo Lee, Byeong-Ho Jeong, Yeonghee Eun, et al.
The Annals of Thoracic Surgery|February 21, 2026
Prognosis of Isolated Cervical Node Recurrence Following Esophagectomy With Two-Field Lymphadenectomy for Esophageal Squamous Cell CarcinomaYeong Jeong Jeon, Jeong A Son, Junghee Lee, et al.
Urologic Oncology|December 24, 2013
FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapyJi-Youn Sung, Jong-Mu Sun, Byong Chang Jeong, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 15, 2022
Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 TrialJiyun Lee, Jiae Koh, Hee Kyung Kim, et al.
Esophagus : Official Journal of the Japan Esophageal Society|December 11, 2023
Prognostic role of pathologic status other than complete response after neoadjuvant therapy followed by surgery in esophageal squamous cell carcinomaSeong Yong Park, Junghee Lee, Dongryul Oh, et al.
Cancer Research and Treatment|October 17, 2023
Neoadjuvant Nivolumab Therapy for Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II StudySehhoon Park, Yurimi Lee, Jiyun Lee, et al.
The Lancet. Oncology|December 25, 2025
Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trialChih-Hung Hsu, Zhihao Lu, Shegan Gao, et al.
Lung Cancer (Amsterdam, Netherlands)|August 14, 2009
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancerJong-Mu Sun, Do-Youn Oh, Se-Hoon Lee, et al.
Journal of Cancer Research and Clinical Oncology|June 1, 2011
Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancySoohyeon Lee, Youngwook Kim, Jong-Mu Sun, et al.
Pageof 31